Prevalence and prognosis of increased pancreatic enzymes in patients with COVID-19: A systematic review and meta-analysis.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Author
Yang, FengXu, Yecheng
Dong, Yinlei
Huang, Yuting
Fu, Yunting
Li, Tian
Sun, Chenyu
Pandanaboyana, Sanjay
Windsor, John A
Fu, Deliang
Date
2022-03-25Journal
PancreatologyPublisher
ElsevierType
Article
Metadata
Show full item recordSee at
https://doi.org/10.1016/j.pan.2022.03.014https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/35361531/
Abstract
Introduction: The prevalence of increased pancreatic enzymes (elevated serum amylase and/or lipase) and its relationship to clinical outcomes in patients with coronavirus disease 2019 (COVID-19) infection is not known. Methods: A systematic review and meta-analysis of relevant studies reporting prevalence and impact of increased pancreatic enzymes (defined as an elevation in amylase and/or lipase levels above the upper limit of normal [ULN] value) in COVID-19 was undertaken. Results: A total of 36,496 patients from 21 studies were included for this meta-analysis. The overall prevalence and mortality for increased pancreatic enzymes (>ULN) in COVID-19 were 25.4% (95% CI, 15.8%-36.2%) and 34.6% (95% CI, 25.5%-44.4%), respectively. The overall prevalence and mortality for increased pancreatic enzymes (>3 × ULN) were 6.1% (95% CI, 3.6%-9.2%) and 39.2% (95% CI, 18.7%-61.6%), respectively. Patients with increased pancreatic enzymes, including elevated serum lipase or amylase of either type, had worse clinical outcomes, including need for ICU admission, mechanical ventilation and mortality. Discussion: Increased pancreatic enzymes is frequent and may exacerbate the consequences of COVID-19 infection.Rights/Terms
Copyright © 2022 IAP and EPC. Published by Elsevier B.V. All rights reserved.Identifier to cite or link to this item
http://hdl.handle.net/10713/18445ae974a485f413a2113503eed53cd6c53
10.1016/j.pan.2022.03.014
Scopus Count
Related articles
- Prevalence and Outcomes of Pancreatic Enzymes Elevation in Patients With COVID-19: A Meta-Analysis and Systematic Review.
- Authors: Zhou Y, Ge YT, Yang XX, Cai Q, Ding YB, Hu LH, Lu GT
- Issue date: 2022
- Pancreatic damage in COVID-19: Why? How?
- Authors: Bacaksız F, Ebik B, Ekin N, Kılıc J
- Issue date: 2021 Oct
- COVID-19 and Serum Amylase and Lipase Levels.
- Authors: Prasad H, Ghetla SR, Butala U, Kesarkar A, Parab S
- Issue date: 2022 May 11
- [Analysis Of Pancreatic Function In Pediatric Patients With Covid-19].
- Authors: Gutiérrez MÁM, Villar MJA, Antonio Ruíz Domínguez J, Cardelús BS, Cuartero BG, en representación del Grupo de Investigación en Patología Endocrinológica Infantil Urgente.
- Issue date: 2022 May 20